On the Koop thing:
A few weeks ago there was a huge write up in the NY Times on the ethics problems Dr. Koop has become entangled in. While no one was suggesting any improper action on his part, there was the problem of where does Dr. Koop quit being the impartial dispenser of medical advice and becomes a drug or treatment salemsman?
Yes, the company enjoyed great marketing name recognition when Dr. Koop got involved, but this came with a price. Over the long run, it will be the quality of the site, its content, that will win the battle of the web site medicine portals.
On the technicals of this stock:
If you follow point and figure at all, this stock is getting close to a possible bullish catapult. Not yet, but close. In any event, the technicals are looking better than they have in a long time.
I'll post if there is any change.
Regards,
Jack Simmons |
